HCPLive

Heart Failure Total Cost Estimated at $70 Billion by 2030

THURSDAY, April 25 (HealthDay News) -- The impact of heart failure is likely to increase, with more than eight million U.S. adults anticipated to have heart failure by 2030, at an estimated total cost of $70 billion, according to a study published online April 24 in Circulation: Heart Failure.

Paul A. Heidenreich, MD, from Stanford University, in California, and colleagues estimated the epidemiology and future costs of heart failure from 2012 to 2030, based on a model that assumes heart failure prevalence will remain constant and that the costs and technological innovation will continue to increase at the same rate.

The researchers projected that more than eight million people in the Unites States will have heart failure by 2030. The direct costs of medications are expected to increase from $21 billion in 2012 to $53 billion in 2030. The estimated total costs, including indirect costs, are expected to increase from $31 billion to $70 billion. Assuming all costs of cardiac care for patients with heart failure are attributable to heart failure, and not to comorbid conditions, the cost estimates projected for 2030 would be $160 billion in direct costs.

"Assuming continuation in present practice patterns, the cost of heart failure is projected to increase markedly over the next 18 years based on demographic changes in the population," the authors write. "The cost would be substantial, with each U.S. adult, on average, paying $244 annually by 2030 to care for the 10 million patients with heart failure."

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

The US had been found to have a higher percentage of opioid use than in any other country.
While children with HIV may have low levels of a key immune cell, a new study shows that most will recover the cell with proper treatment.
Patients administered minimally invasive surgery (MIS) colon resection procedures instead of open surgery leave the hospital quicker and require less follow up with physicians and fewer medical prescriptions.
Researchers will no longer have to test Ebola virus vaccines using the virus strain from the 1976 Zaire outbreak because the results from phase 1 of a new trial are in.
$vAR$